Compared with placebo , adjunctive aripiprazole increased the likelihood of response in all subgroups ( risk ratio [ 95 % CI ] : mild , 1.50 [ 1.15 , 1.95 ] ; moderate , 1.51 [ 1.09 , 2.11 ] ; severe , 1.95 [ 1.23 , 3.10 ] ) .